^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Glioma
    Drug:Farydak (panobinostat) (HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    J Neurooncol
    Title:

    IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat

    Published date:
    08/23/2021
    Excerpt:
    IDH1mut gliomas exhibited marked upregulation of genes associated with the HDAC activity. Glioma cell cultures bearing IDH1mut were significantly more sensitive to the cytotoxic and antiproliferative effects of panobinostat, compared to IDH1wt glioma cells.
    DOI:
    10.1007/s11060-021-03829-0